Belt-Tightening Biogen Looks To Narrow Therapeutic Focus
This article was originally published in The Pink Sheet Daily
Executive Summary
Rising Tecfidera sales not enough to offset perceived need for 11% staff cut and pruning of the pipeline, CEO states.
You may also be interested in...
Spotlight Returns To Biogen R&D To Sustain Success
After an impressive commercial run for Biogen Idec, with four drug launches in two years, it’s up to R&D to deliver more innovative medicines. The bar is high in the areas of neurology Biogen is exploring; Chief Medical Officer Alfred Sandrock discussed the company’s R&D momentum in a recent interview.
ABPI President Steps Down Amid Novo Nordisk Code Of Practice Breach
The president of the Association of the British Pharmaceutical Industry and UK head of Novo Nordisk, Pinder Sahorta, has resigned from the role at the association after the company breached the ABPI Code of Practice.
Nimbus CEO Talks $4bn Takeda Deal And Capital Cycles
In December 2022, Nimbus Inc. completed one of the largest single-asset deals in the history of biotech, selling their TYK2 inhibitor program NDI-034858 for an up-front payment of $4bn and up to $2bn in additional milestone payments. What was it like to close a deal of that magnitude? What’s next for Nimbus? The company‘s CEO, Jeb Keiper, reflected on these questions in a recent interview with In Vivo.